Licensing deals

Relmada dumps depression asset after slew of phase 3 failures

The biotech has terminated the license agreement for esmethadone, months after canceling two phase 3 trials that were not expected to hit their goals.

Darren Incorvaia Jul 11, 2025 12:12pm

Glowing puzzle piece fitting into puzzle

Eolas regains opioid use disorder drug abandoned by AstraZeneca

Jul 10, 2025 9:33am

reshuffle pipeline target reorganize shift change

AstraZeneca’s Alexion pens $825M AAV capsid pact with JCR

Jul 9, 2025 4:52am

Fierce Pharma

Summit in high-stakes deal talks with AstraZeneca: Bloomberg

Jul 7, 2025 10:45am

Processa hands cancer drug back to Opus over time, cost involved

Jul 1, 2025 11:12am

graphic art of a right hand signing something

Sanofi takes up option on Adagene bispecific, invests $25M

Jul 1, 2025 8:10am